Shanghai Fosun Pharmaceutical

Fosun Pharma was established in 1994 and is a healthcare group covering all key sectors of the healthcare industry chain, including pharmaceutical manufacturing, R&D, healthcare services, medical devices, medical diagnosis, pharmaceutical distribution and retail, and more. The company has R&D teams located in China, India, the US and other locations. The company is currently focused on therapeutic areas that include oncology, the cardiovascular system, the central nervous system, the blood system, metabolism and the alimentary system and anti-infection. In its healthcare service segment, Fosun Pharma Group operates in high-end medical centres in developed coastal cities, as well as in specialised and general hospitals in second- and third-tier cities. These include Chancheng Hospital, Hengsheng Hospital, Zhongwu Hospital, Wenzhou Geriatrics Hospital, Guangji Hospital, Jimin Cancer Hospital, Zhuhai Chancheng and Wuhan Jihe Hospital, and more. In 2018, the combined number of authorised beds controlled by Fosun Pharma reached 4,118. In fiscal 2018, the company’s financial highlights included RMB 24.92 billion in revenue, representing an increase of 34.45%. In 2019, the company announced that its investigational drug ORIN1001 has received Fast Track designation (FTD) from the FDA for the treatment of patients with relapsed, refractory and metastatic breast cancer. Add this instrument to your portfolio and trade 02196.HK.